[
  {
    "ts": null,
    "headline": "Africa Pharmaceuticals Market Analysis, Growth Trends, and Forecast Report 2025-2032 | Urbanization and NCDs Drive Demand, Regulatory Harmonization & Local Production Boost Growth",
    "summary": "Africa's pharmaceutical sector is transforming due to chronic disease prevalence, regulatory harmonization, and local production initiatives. Projected to rise from USD 64.2 billion in 2025 to USD 118.3 billion by 2032, the market is set for a 9.10% CAGR. Key players include Sanofi, Pfizer, and GSK.Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Africa Pharmaceuticals Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user\"",
    "url": "https://finnhub.io/api/news?id=e2424e64d61a1e6d263bccba1d87ab6f901de4cf68c71a745f25f9019a52d409",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753283400,
      "headline": "Africa Pharmaceuticals Market Analysis, Growth Trends, and Forecast Report 2025-2032 | Urbanization and NCDs Drive Demand, Regulatory Harmonization & Local Production Boost Growth",
      "id": 136045448,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Africa's pharmaceutical sector is transforming due to chronic disease prevalence, regulatory harmonization, and local production initiatives. Projected to rise from USD 64.2 billion in 2025 to USD 118.3 billion by 2032, the market is set for a 9.10% CAGR. Key players include Sanofi, Pfizer, and GSK.Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Africa Pharmaceuticals Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user\"",
      "url": "https://finnhub.io/api/news?id=e2424e64d61a1e6d263bccba1d87ab6f901de4cf68c71a745f25f9019a52d409"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings",
    "summary": "PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.",
    "url": "https://finnhub.io/api/news?id=68a47e716813bab84ba2240659b98a6d1253986406d1de3d41df947c154337f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753280040,
      "headline": "Here's What to Expect From Pfizer's Non-Oncology Drugs in Q2 Earnings",
      "id": 136062449,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.",
      "url": "https://finnhub.io/api/news?id=68a47e716813bab84ba2240659b98a6d1253986406d1de3d41df947c154337f7"
    }
  },
  {
    "ts": null,
    "headline": "Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion",
    "summary": "The rheumatoid arthritis therapeutics market, valued at USD 29.50 billion in 2024, is set to grow at a 4.60% CAGR, reaching USD 46.26 billion by 2034. Key drivers include rising RA cases, aging populations, and increased generic drug approvals. Leading companies include Pfizer, Amgen, and Novartis. Rheumatoid Arthritis Therapeutics Market Rheumatoid Arthritis Therapeutics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034\"",
    "url": "https://finnhub.io/api/news?id=85af9737bfa9a97ac80e9972b4e62a22f5afc371fd22ebd67169d5f0feaec313",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753279380,
      "headline": "Rheumatoid Arthritis Therapeutics Market Forecast Report 2025-2034 | Rising Preference for Combination Therapies, and Entry of Generic Drugs Supports Expansion",
      "id": 136045425,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The rheumatoid arthritis therapeutics market, valued at USD 29.50 billion in 2024, is set to grow at a 4.60% CAGR, reaching USD 46.26 billion by 2034. Key drivers include rising RA cases, aging populations, and increased generic drug approvals. Leading companies include Pfizer, Amgen, and Novartis. Rheumatoid Arthritis Therapeutics Market Rheumatoid Arthritis Therapeutics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Rheumatoid Arthritis Therapeutics Market Report and Forecast 2025-2034\"",
      "url": "https://finnhub.io/api/news?id=85af9737bfa9a97ac80e9972b4e62a22f5afc371fd22ebd67169d5f0feaec313"
    }
  },
  {
    "ts": null,
    "headline": "Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results",
    "summary": "Shares of Abivax hit the stratosphere Wednesday after the firm unveiled \"potentially disruptive\" results for its ulcerative colitis drug.",
    "url": "https://finnhub.io/api/news?id=740c5c3502a0118d2c436b26dd81a40b6f26e2b2e383432128c1d36022ac9e97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753276507,
      "headline": "Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results",
      "id": 136044154,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of Abivax hit the stratosphere Wednesday after the firm unveiled \"potentially disruptive\" results for its ulcerative colitis drug.",
      "url": "https://finnhub.io/api/news?id=740c5c3502a0118d2c436b26dd81a40b6f26e2b2e383432128c1d36022ac9e97"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
    "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
    "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753258140,
      "headline": "Cancer Pain 8 Major Market Forecast Report 2025-2034 | Opioids and Non-Opioids Drive Innovations, Medical Cannabis Emerges as Alternative",
      "id": 136039626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson. Cancer Pain Market Cancer Pain Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Cancer Pain Market Report and Forecast 2025-2034\" report has been added to ResearchAndMarkets.com's offering.The canc",
      "url": "https://finnhub.io/api/news?id=cd387d7651a3df8bb96f38bcdf02db1a89535f3ab4083bcf6a56127b0a5f35ba"
    }
  },
  {
    "ts": null,
    "headline": "Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances",
    "summary": "The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals like LEO Pharma's tralokinumab-ldrm, and novel treatments. Major players include AbbVie, Pfizer, and Regeneron. Atopic Dermatitis Market Atopic Dermatitis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Atopic Dermatitis Market Report and Forecast 2025-2034\" report has been added to ResearchA",
    "url": "https://finnhub.io/api/news?id=9bf7f683fd614ffa47b5eb4949231acd9dc19d386149783b004bef4232492def",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753258080,
      "headline": "Atopic Dermatitis Market Forecast Report 2025-2034 | FDA Approval of Tralokinumab-Ldrm Stimulates Treatment Advances",
      "id": 136039632,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals like LEO Pharma's tralokinumab-ldrm, and novel treatments. Major players include AbbVie, Pfizer, and Regeneron. Atopic Dermatitis Market Atopic Dermatitis Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The \"Atopic Dermatitis Market Report and Forecast 2025-2034\" report has been added to ResearchA",
      "url": "https://finnhub.io/api/news?id=9bf7f683fd614ffa47b5eb4949231acd9dc19d386149783b004bef4232492def"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Building The Next Oncology Empire",
    "summary": "Pfizer: Building The Next Oncology Empire",
    "url": "https://finnhub.io/api/news?id=cf0b9c6bb908568b634a846b27c713d1dd35f1e483850eb53c06ab71113c9132",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753243977,
      "headline": "Pfizer: Building The Next Oncology Empire",
      "id": 136039403,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cf0b9c6bb908568b634a846b27c713d1dd35f1e483850eb53c06ab71113c9132"
    }
  },
  {
    "ts": null,
    "headline": "Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income",
    "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Regency Centers, Tyson Foods, and Pfizer have rewarded shareholders for years and recently announced dividend increases. These ...",
    "url": "https://finnhub.io/api/news?id=efc0bd29fe005f3cbeb34334ec801183f55fe505fb72cd308945bf9a05efc10a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753236032,
      "headline": "Why Regency Centers, Tyson Foods, And Pfizer Are Winners For Passive Income",
      "id": 136038295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Regency Centers, Tyson Foods, and Pfizer have rewarded shareholders for years and recently announced dividend increases. These ...",
      "url": "https://finnhub.io/api/news?id=efc0bd29fe005f3cbeb34334ec801183f55fe505fb72cd308945bf9a05efc10a"
    }
  }
]